Overview of iCMLf programs
The iCMLf is committed to improving the outcomes for CML patients globally. The aim of the iCMLf is to foster and coordinate global clinical and research collaborations and to improve clinical practice and disease monitoring in CML. To achieve these goals the foundation coordinates numerous programs that mainly focus on education and access to treatment and diagnosis, primarily for emerging regions. The iCMLf current activities relate to three core areas:
- Intensive educational programs for physicians unable to easily access international meetings
- Increasing access to CML diagnostics to improve patient outcomes
- Online education to spread best practice
The Emerging Regions Support and Partnership (ERSAP) Programs focus on areas with limited resources to manage CML and this is the primary focus of the Foundation.
Educational programs
The iCMLf Conversations
The iCMLf hosts regular live webinars with renowned experts discussing various topics in CML management. The series of expert talks also includes webinars on CML and COVID-19 in English and other languages. All past conversations are available to view on-demand on the iCMLf website.
The iCMLf Clinical Preceptorship Program (ERSAP)
This program enhances clinical knowledge and skills in the treatment of CML for clinicians from emerging economic regions through preceptorships at internationally renowned CML centres. Participants of the program become part of the clinical team at the host site for the duration of the preceptorship, undertaking seminars and laboratory work where appropriate.
The iCMLf Forum for Physicians from Emerging Regions (ERSAP)
This iCMLf Forum, held annually, is a partnership project between the iCMLf and The Max Foundation. The aim of the meeting is to on the challenges faced by physicians in emerging economic regions, where resources are often limited, and to share the work and initiatives implemented to overcome these. The iCMLf Forum showcases specific topics relevant to these regions, highlighting local projects that enhance CML patient management.
The iCMLf Virtual Education Program (international)
The Virtual Education Program offers a series of webcast presentations from leading hematologists. These presentations provide updated information on treatment advances and best practice management of CML, including disease monitoring and new therapies. There are modules available in English, French and Spanish.
Clinical Case Discussion Forum (international)
This discussion forum on the iCMLf website aims to share and enhance best practice management of CML. Clinicians can post difficult or interesting CML patient cases for discussion. Each clinical case is forwarded to the iCMLf expert clinical panel for a brief independent response. The topic is then opened for discussion and comment in the online forum.
Read more here
Access to CML Diagnostics
The Diagnosis and Testing Program (ERSAP)
The iCMLf Diagnosis and Testing Program provides diagnostic testing and ultimately disease monitoring for CML patients in emerging economic countries where this is limited or not currently available. Through the Program the iCMLf will build capacity at a local level to bring high quality testing to the patient, or to develop a low cost strategy for sending patient samples to a central referral laboratory for testing.
Finding a cure for CML
The iCMLf Genomic Alliance
The iCMLf has established the iCMLf Genomics Alliance with the aim to harness the wealth of genomic information that is generated in local CML research projects by building a platform to facilitate data assimilation and sample exchanges. Combining many data sets and facilitating global collaboration studies will enable us to better understand the relationship between genomic aberrations and patient outcomes.
The iCMLf TFR Alliance
The iCMLf also formed a second Alliance under the banner of CURE - the iCMLf Treatment-Free-Remission (TFR) Alliance to establish a global registry for TFR cases. The purpose of the global registry is to develop and validate predictors of TFR success, look at other aspects of TFR outcomes, and (critically) facilitate exchange of clinically annotated samples from registry patients to further our understanding about the biological and molecular features of TFR.